Nonclassical Axis of the Renin-Angiotensin System and Neprilysin: Key Mediators That Underlie the Cardioprotective Effect of PPAR-Alpha Activation during Myocardial Ischemia in a Metabolic Syndrome Model

The activation of the renin-angiotensin system (RAS) participates in the development of metabolic syndrome (MetS) and in heart failure. PPAR-alpha activation by fenofibrate reverts some of the effects caused by these pathologies. Recently, nonclassical RAS components have been implicated in the pathogenesis of hypertension and myocardial dysfunction; however, their cardiac functions are still controversial. We evaluated if the nonclassical RAS signaling pathways, directed by angiotensin III and angiotensin-(1-7), are involved in the cardioprotective effect of fenofibrate during ischemia in MetS rats. Control (CT) and MetS rats were divided into the following groups: (a) sham, (b) vehicle-treated myocardial infarction (MI-V), and (c) fenofibrate-treated myocardial infarction (MI-F). Angiotensin III and angiotensin IV levels and insulin increased the aminopeptidase (IRAP) expression and decreased the angiotensin-converting enzyme 2 (ACE2) expression in the hearts from MetS rats. Ischemia activated the angiotensin-converting enzyme (ACE)/angiotensin II/angiotensin receptor 1 (AT1R) and angiotensin III/angiotensin IV/angiotensin receptor 4 (AT4R)-IRAP axes. Fenofibrate treatment prevented the damage due to ischemia in MetS rats by favoring the angiotensin-(1-7)/angiotensin receptor 2 (AT2R) axis and inhibiting the angiotensin III/angiotensin IV/AT4R-IRAP signaling pathway. Additionally, fenofibrate downregulated neprilysin expression and increased bradykinin production. These effects of PPAR-alpha activation were accompanied by a reduction in the size of the myocardial infarct and in the activity of serum creatine kinase. Thus, the regulation of the nonclassical axis of RAS forms part of a novel protective effect of fenofibrate in myocardial ischemia.

[1]  Juan Liang,et al.  Cardioprotection of cortistatin against isoproterenol-induced myocardial injury in rats , 2020, Annals of translational medicine.

[2]  A. Sánchez-Mendoza,et al.  Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model , 2019, Molecules.

[3]  B. Trachtenberg,et al.  Recent advances in heart failure , 2018, Current opinion in cardiology.

[4]  A. Ferreira,et al.  Cardiovascular effects of small peptides of the renin angiotensin system , 2017, Physiological reports.

[5]  J. Tune,et al.  Cardiovascular consequences of metabolic syndrome. , 2017, Translational research : the journal of laboratory and clinical medicine.

[6]  Y. Koh,et al.  Neprilysin facilitates adipogenesis through potentiation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway , 2017, Molecular and Cellular Biochemistry.

[7]  A. Owens,et al.  Neprilysin Inhibitors: Emerging Therapy for Heart Failure. , 2017, Annual review of medicine.

[8]  A. Sánchez-Mendoza,et al.  Fenofibrate Therapy Restores Antioxidant Protection and Improves Myocardial Insulin Resistance in a Rat Model of Metabolic Syndrome and Myocardial Ischemia: The Role of Angiotensin II , 2016, Molecules.

[9]  Yiming Li,et al.  Beneficial Effects of Combined AT1 Receptor/Neprilysin Inhibition (ARNI) Versus AT1 Receptor Blockade Alone in the Diabetic Eye , 2016, Investigative ophthalmology & visual science.

[10]  K. Krskova,et al.  Alternative renin-angiotensin system pathways in adipose tissue and their role in the pathogenesis of obesity , 2016, Endocrine regulations.

[11]  J. Gutkowska,et al.  Oxytocin and cardioprotection in diabetes and obesity , 2016, BMC Endocrine Disorders.

[12]  Suhn Hee Kim,et al.  Angiotensin IV protects cardiac reperfusion injury by inhibiting apoptosis and inflammation via AT4R in rats , 2016, Peptides.

[13]  J. Åqvist,et al.  Binding to and Inhibition of Insulin-Regulated Aminopeptidase by Macrocyclic Disulfides Enhances Spine Density , 2016, Molecular Pharmacology.

[14]  A. Sánchez-Mendoza,et al.  Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model , 2016, PPAR research.

[15]  N. Brown,et al.  Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition , 2016, Circulation.

[16]  S. Saleh,et al.  Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression. , 2016, World journal of gastroenterology.

[17]  Jie Yuan,et al.  PPARα activation by fenofibrate protects against acute myocardial ischemia / reperfusion injury by inhibiting mitochondrial apoptosis , 2016 .

[18]  Nirmal Singh,et al.  Bradykinin in ischemic conditioning-induced tissue protection: Evidences and possible mechanisms. , 2015, European journal of pharmacology.

[19]  M. Ramírez-Ortega,et al.  PPAR&agr; Stimulation Modulates Myocardial Ischemia-induced Activation of Renin–Angiotensin System , 2015, Journal of cardiovascular pharmacology.

[20]  Shan Jia,et al.  ACE2-Ang (1-7) axis is induced in pressure overloaded rat model. , 2015, International journal of clinical and experimental pathology.

[21]  C. Llorens-Cortes,et al.  A new strategy for treating hypertension by blocking the activity of the brain renin-angiotensin system with aminopeptidase A inhibitors. , 2014, Clinical science.

[22]  L. Valle-Mondragón,et al.  Angiotensin II and 1-7 during aging in Metabolic Syndrome rats. Expression of AT1, AT2 and Mas receptors in abdominal white adipose tissue , 2014, Peptides.

[23]  R. Widdop,et al.  The Protective Arms of the Renin-Angiontensin System in Stroke , 2014, Current Hypertension Reports.

[24]  X. Li,et al.  New Frontiers in the Intrarenal Renin-Angiotensin System: A Critical Review of Classical and New Paradigms , 2013, Front. Endocrinol..

[25]  G. Sesti,et al.  Angiotensin (1-7) counteracts the negative effect of angiotensin II on insulin signalling in HUVECs. , 2013, Cardiovascular research.

[26]  N. Brown,et al.  Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension , 2013, Journal of hypertension.

[27]  R. Santos,et al.  Angiotensin-(1-7): beyond the cardio-renal actions. , 2013, Clinical science.

[28]  I. Biton,et al.  Angiotensin 1-7 as Means to Prevent the Metabolic Syndrome , 2013, Diabetes.

[29]  A. Ferreira,et al.  Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. , 2013, The Journal of endocrinology.

[30]  R. Eckel,et al.  Fenofibrate Improves Vascular Endothelial Function by Reducing Oxidative Stress While Increasing Endothelial Nitric Oxide Synthase in Healthy Normolipidemic Older Adults , 2012, Hypertension.

[31]  J. Jalil,et al.  Protective Role of the ACE2/Ang-(1–9) Axis in Cardiovascular Remodeling , 2012, International journal of hypertension.

[32]  A. Christopoulos,et al.  Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. , 2011, Clinical science.

[33]  O. Carretero,et al.  The kallikrein-kinin system as a regulator of cardiovascular and renal function. , 2011, Comprehensive Physiology.

[34]  N. Bogdanovic,et al.  PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism. , 2011, Journal of Alzheimer's disease : JAD.

[35]  J. Gutkowska,et al.  Oxytocin increases glucose uptake in neonatal rat cardiomyocytes. , 2010, Endocrinology.

[36]  S. Keidar,et al.  ACE2 of the heart: From angiotensin I to angiotensin (1-7). , 2007, Cardiovascular research.

[37]  T. Fukushima,et al.  Correlation among clinicopathological parameters of myocardial damage in rats treated with isoproterenol. , 2007, Experimental animals.

[38]  W. Buczko,et al.  The physiological significance of the alternative pathways of angiotensin II production. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[39]  F. Ceriotti,et al.  IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. , 2006, Clinical chemistry and laboratory medicine.

[40]  J. Egido,et al.  Angiotensin IV Activates the Nuclear Transcription Factor-&kgr;B and Related Proinflammatory Genes in Vascular Smooth Muscle Cells , 2005, Circulation research.

[41]  S. Ye,et al.  The angiotensin IV/AT4 receptor. , 2004, Cellular and molecular life sciences : CMLS.

[42]  S. Keller.  Role of the insulin-regulated aminopeptidase IRAP in insulin action and diabetes. , 2004, Biological & pharmaceutical bulletin.

[43]  M. Goddard,et al.  ACE2 gene expression is up-regulated in the human failing heart , 2004, BMC medicine.

[44]  S. Ye,et al.  What’s new in the renin-angiotensin system? , 2004, Cellular and Molecular Life Sciences CMLS.

[45]  C. Visser,et al.  Apoptosis in myocardial ischaemia and infarction , 2002, Journal of clinical pathology.

[46]  M. Panteghini,et al.  IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37°C. Part 2. Reference Procedure for the Measurement of Catalytic Concentration of Creatine Kinase , 2002, Clinical chemistry and laboratory medicine.